AZTA
Azenta, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
37.40
▲ 0.89 (2.44%)
MARKET · —
Price
Open
36.51
Prev close
36.51
Day high
37.49
Day low
36.05
Volume
644.66K
Market cap
$1.64B
P/E (TTM)
—
52W range
15.93 – 41.73
Trailing performance
Returnvs SPY
1W
+12.04%
+13.4%
1M
+32.16%
+28.4%
3M
+91.40%
+88.3%
6M
+27.73%
+16.7%
YTD
+12.45%
+0.2%
1Y
+25.63%
+5.6%
3Y
-32.15%
-106.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.64B
Enterprise value$1.37B
Revenue (TTM)$613.81M
Gross profit$270.37M
EBITDA$33.01M
Net income$-112.09M
EPS (TTM)$-2.46
Free cash flow$63.37M
Total cash$325.80M
Total debt$53.97M
Book value / share$34.51
Shares outstanding43.81M
Float38.38M
Short % of float19.82%
Dividend yield—
Beta (5Y)1.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E63.39
PEG ratio0.53
Price / sales—
Price / book1.08
EV / revenue2.23
EV / EBITDA41.41
Gross margin44.05%
Operating margin-2.27%
Profit margin-20.02%
Return on equity-7.04%
Return on assets-0.73%
Debt / equity3.57
Current ratio2.50
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $593.82M | $656.32M | $665.07M | $555.50M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$59.50M | -$164.17M | -$14.26M | $2.13B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$59.50M | -$164.17M | -$14.26M | $2.13B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.10 | 0.16 | +60.0% |
| Mar 2026 | 0.14 | -0.04 | -129.0% |
| Dec 2025 | 0.13 | 0.09 | -33.0% |
| Sep 2025 | 0.20 | 0.21 | +7.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.16 | 5 | $160.32M | +0.7% |
| Next quarter | 0.12 | 3 | $155.55M | +4.7% |
| Current year | 0.37 | 5 | $614.97M | +3.6% |
| Next year | 0.59 | 5 | $641.75M | +4.4% |
Analyst targets & ownership
Mean target$34.80
High target$37.00
Low target$33.00
Implied upside-6.95%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 2
Hold3
Sell / Strong sell0 / 0
Held by insiders1.05%
Held by institutions117.30%
Institutions holding347
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
461.30K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | STARR EPHRAIM General Counsel |
BUY | 335 | $8.10K | Direct |
| May 18, 26 | CORNOG WILLIAM L. Director |
BUY | 10.00K | $163.80K | Indirect |
| Apr 28, 26 | MARTIN WILLIAM E III Officer |
STOCK | 17.79K | $431.23K | Direct |
| Feb 6, 26 | NOVA TINA SUSAN Director |
STOCK | 5.66K | $157.72K | Direct |
| Feb 5, 26 | KOFFEY QUENTIN Director |
STOCK | 5.66K | $0 | Direct |
| Feb 5, 26 | DOSHI DIPAL Director |
STOCK | 5.66K | $157.72K | Direct |
| Feb 5, 26 | MCLAUGHLIN ERICA Director |
STOCK | 5.66K | $157.72K | Direct |
| Feb 5, 26 | CASAL FRANK Director |
STOCK | 7.24K | $201.72K | Direct |
| Nov 24, 25 | MAROTTA JOHN Chief Executive Officer |
STOCK | 122.27K | $0 | Direct |
| Nov 24, 25 | MAROTTA JOHN Chief Executive Officer |
STOCK | 118.19K | $0 | Direct |
| Nov 24, 25 | ZHOU GINGER Officer |
STOCK | 13.04K | $0 | Direct |
| Nov 24, 25 | PIROGOVA OLGA Officer |
STOCK | 16.30K | $0 | Direct |
| Nov 24, 25 | LIN LAWRENCE Y Chief Financial Officer |
STOCK | 36.68K | $0 | Direct |
| Nov 24, 25 | STARR EPHRAIM General Counsel |
STOCK | 34.23K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CUETO HERMAN |
Chief Financial Officer | 23.89K | Sale |
DAVIS ROBYN C |
Director | 33.63K | Stock Award(Grant) |
JOSEPH JASON W |
General Counsel | 112.56K | Sale |
KOFFEY QUENTIN |
Director | 4.62M | Stock Award(Grant) |
LIN LAWRENCE Y |
Chief Financial Officer | 79.66K | Stock Award(Grant) |
MAROTTA JOHN |
Chief Executive Officer | 217.27K | Stock Award(Grant) |
PIROGOVA OLGA |
Officer | 33.04K | Stock Award(Grant) |
STARR EPHRAIM |
General Counsel | 68.73K | Purchase |
WANG DAVID DONG |
Officer | 24.11K | Sale |
ZHOU GINGER |
Officer | 38.76K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
34.36
+8.84% from price
SMA 20
31.99
+16.89% from price
SMA 50
27.84
+34.36% from price
SMA 100
24.96
+49.84% from price
SMA 200
28.19
+32.68% from price
EMA 12
33.95
+10.16% from price
EMA 26
31.51
+18.68% from price
EMA 50
29.01
+28.91% from price
RSI (14)
78.7
Overbought
MACD (12,26,9)
2.44
Hist 0.33
ATR (14)
1.51
4.04% of price
Realised vol 30D
46.1%
Annualised
Bollinger upper
37.58
20, 2σ
Bollinger lower
26.41
20, 2σ
50 / 200 cross
Death
27.84 vs 28.19
Trend bias
Above 200
+32.68%
Risk profile
Beta vs SPY
1.47
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
46.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-60.9%
Peak to trough
Max drawdown 5Y
-87.1%
Peak to trough
ATR 14
1.51
4.04% of price
Beta (reported)
1.38
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
17.50
-53.2% from spot
ATM implied vol
53.6%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
2
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
35.00
15 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
1 Momentum Stock for Long-Term Investors and 2 We Find Risky
StockStory · 3d ago
The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call
StockStory · 9d ago
Azenta (AZTA) Q3 2026 Earnings Call Transcript
Motley Fool · 11d ago
Azenta (AZTA) Is Up 6.7% After Raising 2026 Guidance And Completing $50M Buyback – What’s Changed
Simply Wall St. · 16d ago
Life Science Funding Weakness Hit Azenta’s (AZTA) Outlook
Insider Monkey · 16d ago
Azenta Inc (AZTA) (Q3 2026) Earnings Call Highlights: Organic Growth Surges 9% Amid Strategic ...
GuruFocus.com · 17d ago
Azenta Q3 Earnings Call Highlights
MarketBeat · 17d ago
Azenta, Inc. Q3 2026 Earnings Call Summary
Moby · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.